Works matching DE "BIOGEN Inc. (2003- )"
Results: 90
Users Fear that Lymphoma Drugs Will Disappear.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2007, v. 99, n. 7, p. 498, doi. 10.1093/jnci/djk155
- By:
- Publication type:
- Article
MS pills are making news.
- Published in:
- Inside MS, 2007, v. 25, n. 1, p. 28
- Publication type:
- Article
FDA postpones Tysabri decision.
- Published in:
- Inside MS, 2006, v. 24, n. 3, p. 32
- Publication type:
- Article
Advocacy is on my mind.
- Published in:
- Inside MS, 2005, v. 23, n. 4, p. 70
- By:
- Publication type:
- Article
Tysabri suspended.
- Published in:
- Inside MS, 2005, v. 23, n. 2, p. 27
- Publication type:
- Article
FDA asked to review Antegren.
- Published in:
- Inside MS, 2004, v. 22, n. 4, p. 27
- Publication type:
- Article
Biogen Idec restructures, sharpens neurology focus.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 1, p. 7, doi. 10.1038/nbt0111-7
- By:
- Publication type:
- Article
Novartis eyes oral MS drug as potential blockbuster.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 11, p. 1135, doi. 10.1038/nbt1110-1135
- By:
- Publication type:
- Article
People.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 8, p. 876, doi. 10.1038/nbt0810-876
- Publication type:
- Article
How Tysabri survived.
- Published in:
- 2009
- By:
- Publication type:
- Opinion
Tysabri's troubles return.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 10, p. 1061, doi. 10.1038/nbt1008-1061
- By:
- Publication type:
- Article
Start-ups weigh benefits of corporate incubators.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 3, p. 254, doi. 10.1038/nbt0308-254
- By:
- Publication type:
- Article
Biogen Idec goes on the auction block.
- Published in:
- Nature Biotechnology, 2007, v. 25, n. 12, p. 1335, doi. 10.1038/nbt1207-1335
- By:
- Publication type:
- Article
Recent patent applications in protein purification.
- Published in:
- Nature Biotechnology, 2006, v. 24, n. 10, p. 1222, doi. 10.1038/nbt1006-1222
- Publication type:
- Article
Fast track to MS drug.
- Published in:
- Nature Biotechnology, 2004, v. 22, n. 8, p. 939, doi. 10.1038/nbt0804-939
- By:
- Publication type:
- Article
Echoes from the Past: How the Federal Circuit Continues to Struggle with Patentable Subject Matter Post-Bilski.
- Published in:
- Missouri Law Review, 2012, v. 77, n. 2, p. 591
- By:
- Publication type:
- Article
Tysabri's return draws cautious optimism.
- Published in:
- American Journal of Health-System Pharmacy, 2006, v. 63, n. 15, p. 1388, doi. 10.2146/news050092
- By:
- Publication type:
- Article
News Briefs.
- Published in:
- American Journal of Health-System Pharmacy, 2004, v. 61, n. 3, p. 234, doi. 10.1093/ajhp/61.3.234
- Publication type:
- Article
BI3 -- Biogen Idec's Innovation Incubator.
- Published in:
- 2007
- Publication type:
- Product Review
Search and Deploy.
- Published in:
- Bio-IT World, 2006, v. 5, n. 8, p. 24
- By:
- Publication type:
- Article
News Blast.
- Published in:
- Bio-IT World, 2006, v. 5, n. 6, p. 30
- Publication type:
- Article
The Other Guy's Shoes.
- Published in:
- Bio-IT World, 2005, v. 4, n. 1, p. 10
- By:
- Publication type:
- Article
News Blast.
- Published in:
- Bio-IT World, 2004, v. 3, n. 12, p. 8
- Publication type:
- Article
News Blast.
- Published in:
- Bio-IT World, 2004, v. 3, n. 11, p. 10
- Publication type:
- Article
Two Paths, One Molecule.
- Published in:
- Bio-IT World, 2004, v. 3, n. 2, p. 14
- By:
- Publication type:
- Article
Biogen fights takeover bid.
- Published in:
- Nature, 2008, v. 453, n. 7199, p. 1149, doi. 10.1038/4531149a
- By:
- Publication type:
- Article
Market watch.
- Published in:
- Nature, 2007, v. 450, n. 7166, p. 17, doi. 10.1038/450017d
- Publication type:
- Article
Market Watch.
- Published in:
- Nature, 2006, v. 441, n. 7093, p. 573, doi. 10.1038/441573b
- Publication type:
- Article
Medicines Australia clamps down on code breakers.
- Published in:
- Australian Journal of Pharmacy, 2011, v. 92, n. 1089, p. 50
- Publication type:
- Article
Antibody drugs for Alzheimer's show glimmers of promise.
- Published in:
- Nature, 2015, v. 523, n. 7562, p. 509, doi. 10.1038/nature.2015.18031
- By:
- Publication type:
- Article
Drug that boosts nerve signals offers hope for multiple sclerosis.
- Published in:
- Nature, 2015, v. 520, n. 7548, p. 417, doi. 10.1038/520417a
- By:
- Publication type:
- Article
Biogen Idec storms haemophilia markets.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 7, p. 485, doi. 10.1038/nrd4387
- Publication type:
- Article
Drug makers and NIH team up to find and validate targets.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 4, p. 241, doi. 10.1038/nrd4293
- By:
- Publication type:
- Article
Deal watch: Biogen and Amicus to pursue genetically validated Parkinson's disease target.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 11, p. 819, doi. 10.1038/nrd4166
- By:
- Publication type:
- Article
Big expectations for Biogen's small MS drug.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 5, p. 333, doi. 10.1038/nrd4087
- Publication type:
- Article
When Rotation Doesn't Work.
- Published in:
- Internal Auditor, 2009, v. 66, n. 5, p. 67
- Publication type:
- Article
A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
- Published in:
- 2021
- By:
- Publication type:
- journal article
BUSINESS AND PEOPLE UPDATE.
- Published in:
- Applied Clinical Trials, 2007, v. 16, n. 2, p. 74
- Publication type:
- Article
G100 LIST TURNOVER RATE IN 2017: 35%.
- Published in:
- Corporate Knights, 2017, v. 16, n. 1, p. 38
- Publication type:
- Article
REACH FOR THE TOP.
- Published in:
- Corporate Knights, 2015, v. 14, n. 1, p. 40
- By:
- Publication type:
- Article
G 100 THE GLOBAL 100 MOST SUSTAINABLE CORPORATIONS.
- Published in:
- Corporate Knights, 2015, v. 14, n. 1, p. 30
- By:
- Publication type:
- Article
THE GLOBAL 100.
- Published in:
- 2014
- By:
- Publication type:
- Chart/Diagram/Graph
News.
- Published in:
- Clinical Infectious Diseases, 2011, v. 52, n. 6, p. i, doi. 10.1093/cid/cir059
- Publication type:
- Article
Impact of recent IP caselaw on biomarkers and personalized medicine.
- Published in:
- Journal of Commercial Biotechnology, 2011, v. 17, n. 2, p. 191, doi. 10.1057/jcb.2010.36
- By:
- Publication type:
- Article
Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 4, p. 260, doi. 10.1038/nrd3708
- By:
- Publication type:
- Article
Deal watch: High hopes for oral SYK inhibitor in rheumatoid arthritis.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 1, p. 10, doi. 10.1038/nrd3631
- By:
- Publication type:
- Article
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 9, p. 647, doi. 10.1038/nrd3547
- Publication type:
- Article
Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 6, p. 404, doi. 10.1038/nrd3465
- Publication type:
- Article
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2010, v. 9, n. 7, p. 508, doi. 10.1038/nrd3218
- By:
- Publication type:
- Article
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2010, v. 9, n. 4, p. 259, doi. 10.1038/nrd3156
- Publication type:
- Article